Skip to article

IMMUNOTHERAPY · MEDICAL INNOVATION

CAR T-Cell Therapy: Understanding Engineered Immune Cells in Cancer Care

What if immune cells could be engineered to recognise cancer-associated targets? CAR T-cell therapy does this and already has a role in selected blood cancers. [1]

Start with the key points
CAR receptor on an engineered T cell recognising a target antigen: simplified educational illustration
Simplified target recognition, not a depiction of treatment outcomes.

THE SHORT ANSWER

CAR T-cell therapy engineers T cells to express a chimeric antigen receptor (CAR), expands them and infuses them into a patient. It is an immune-cell treatment, not a cancer-screening blood test. [2]

  • Established indications concern selected blood cancers.
  • Many solid-tumour applications remain investigational.
  • Patient selection and safety follow-up are essential.

Article information

Reviewer and approver details have not yet been provided. This does not indicate completed medical review or approval.

Written by

NameKavitch Siriatcharanon
OrganisationX-ZELL Diagnostics Clinic

Scientific / medical reviewer

Name______________________
Credentials______________________

Approved by

Name______________________
Position______________________
Published date______________________
Last updated

What is CAR T-cell therapy?

T cells are white blood cells involved in immunity. A CAR is an engineered receptor that enables a T cell to bind a target on a cell’s surface, such as CD19 or BCMA, depending on the product. [2] [4] [5]

A CAR can be thought of as an added signal receiver. The analogy has limits: some targets also occur on healthy cells, and responses differ between patients. [6]

How does CAR T-cell therapy work?

The pathway below illustrates autologous CAR T-cell therapy, which uses the patient’s own cells. Assessment and follow-up require an experienced treatment team. [3] [12]

Illustration of CAR T-cell collection, engineering, expansion, infusion and target recognition
Illustrative cell preparation and infusion. Panel 5 shows target recognition; outcomes vary, and safety monitoring is essential after infusion.
  1. 1

    Collect T cells

    Leukapheresis separates white cells from blood and returns other blood components to the patient.

  2. 2

    Engineer the cells

    Genetic material is introduced into T cells so they can produce the CAR receptor.

  3. 3

    Expand and check

    Cells are expanded and quality-tested before release for treatment.

  4. 4

    Prepare and infuse

    Lymphodepleting chemotherapy commonly precedes the intravenous cell infusion.

  5. 5

    Monitor and follow up

    The team monitors adverse events, assesses response and arranges long-term follow-up.

Five-stage overview. Details and timing depend on the product and treatment plan. [3] [6]

Individual cell manufacture may take several weeks. Interim disease-control treatment may be considered while waiting. The infusion is only one part of the overall care pathway. [12]

Which cancers have established indications?

The examples below refer to U.S. FDA indications in the United States, checked on 6 November 2026. They are not an exhaustive product list or confirmation of Thai FDA registration. [4] [5]

Examples of U.S. indications
Disease groupProduct exampleSelected eligibility conditions
B-cell ALLKYMRIAH [4]Patients up to age 25 with refractory disease or second or later relapse, as specified in the label.
Selected B-cell lymphomasKYMRIAH [4]Certain adults with large B-cell or follicular lymphoma after prior treatment, subject to product-specific criteria.
Multiple myelomaCARVYKTI [5]Adults with relapsed or refractory disease who meet the label’s prior-treatment requirements.

Note: the cited KYMRIAH indication for follicular lymphoma received accelerated approval. Continued approval may depend on confirmatory evidence of clinical benefit, as specified by the FDA. [4]

Eligibility depends on the disease, previous therapies, overall health and local approval. The team assesses infections and organ fitness; a diagnosis alone does not establish suitability. [12]

CAR T-cell therapy and solid tumours

Solid tumours present distinct challenges. Antigen expression can vary within a tumour, its surroundings can suppress immune activity, and T cells may struggle to reach tumour tissue. [1]

Researchers are testing receptor design, cell engineering and local delivery. Early trials in selected cancers are informative, but do not establish a standard treatment for every solid tumour or patient. [9] [13]

Risks and limitations of CAR T-cell therapy

Cytokine release syndrome (CRS)

Immune activation can cause fever, low blood pressure or breathing difficulty. Severity varies, and urgent treatment may be necessary. [7]

Immune effector cell-associated neurotoxicity (ICANS)

Confusion, speech or consciousness changes and, in some cases, seizures require monitoring by the treatment team. [7]

Other risks include infections, low blood counts and longer-term immune effects. Product-specific precautions and the individual’s condition guide care. [14]

The FDA warns about T-cell malignancies after certain CAR T-cell products and recommends lifelong monitoring for secondary cancers. This supports continued follow-up; it does not mean every recipient will develop another cancer. [8]

Personalised manufacture, waiting times and specialist care complicate access. Total costs depend on the product, country and care required; the treating centre should explain costs and coverage. [6] [10]

Future directions for CAR T-cell therapy

Research explores controllable next-generation CARs, multiple-target recognition and more efficient manufacturing. Improving safety and access are goals that require evidence for each approach. [9]

Donor-derived, or allogeneic, cells could be manufactured in advance, but immune rejection and donor–recipient interactions remain challenges. Manufacturing advantages or early trial findings do not establish benefit for everyone. [10]

Frequently asked questions about CAR T-cell therapy

How does it differ from chemotherapy?

CAR T uses engineered immune cells, whereas chemotherapy uses medicines. They may be combined: preparative chemotherapy commonly precedes the cell infusion. [3]

Which cancers can it treat?

Certain B-cell ALL, B-cell lymphomas and multiple myeloma have established indications, depending on the product and country. [4] [5]

Can CAR T-cell therapy cure cancer?

Some patients achieve long remissions, but non-response and relapse remain possible. A cure cannot be guaranteed, and follow-up is necessary. [1]

What side effects can occur?

Important effects include CRS, ICANS, infections and low blood counts. Symptoms and severity vary; report unexpected symptoms to the treatment team. [14]

Is CAR T-cell therapy available in Thailand?

Thailand has research and specialist treatment programmes. Siriraj Hospital has developed and produced CAR T cells domestically and studied their use in selected patients with relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukaemia. Another programme is a collaboration between the Department of Medical Services and Prince of Songkla University. These programmes do not establish Thai FDA registration for every product or eligibility for everyone; confirm current access and criteria with the treating centre. [11] [15] [16]

Key message

CAR T-cell therapy adds options for selected blood cancers, with eligibility, risk and long-term follow-up central to care. Solid-tumour and newer applications need approach-specific evidence. Treatment decisions belong with a specialist team. [2] [12]

References and further reading

Sources checked on 6 November 2026.

  1. National Cancer InstituteCAR T Cells: Engineering Immune Cells to Treat Cancer ↗
  2. National Cancer InstituteT-cell Transfer Therapy ↗
  3. Penn MedicineCell and Gene Therapy ↗
  4. U.S. FDAKYMRIAH: product information and indications ↗
  5. U.S. FDACARVYKTI: product information and indications ↗
  6. American Cancer SocietyCAR T-cell Therapy and Its Side Effects ↗
  7. NHS Specialist Pharmacy ServiceUnderstanding acute CAR-T cell therapy toxicities in adults ↗
  8. U.S. FDABoxed warning for T-cell malignancies following CAR T-cell immunotherapies ↗
  9. National Cancer InstituteEngineering CAR T-Cell Therapy to Overcome Limitations ↗
  10. Peer-reviewed review · PubMedAllogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks ↗
  11. Department of Medical ServicesCAR-T Cell and ATMP collaboration with Prince of Songkla University, 23 December 2025 ↗
  12. University College London Hospitals NHSCAR T-cell therapy patient pathway ↗
  13. National Cancer InstituteGD2 CAR T Cells Show Promise Against Diffuse Midline Glioma ↗
  14. UT MD Anderson Cancer CenterCAR T-cell Therapy Side Effects ↗
  15. Techsauce · 4 November 2025Siriraj CAR T-cell development in Thailand ↗
  16. Siriraj Hospital · Mahidol UniversityCAR T-cell research for blood cancers ↗
Read more health and medical technology articles →